Delivery Order SPE2DB22D3004-SPE2DB25FRD58
Award Date 6/20/25
Potential Completion Date 7/14/25
Potential Value $6.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $11,159.12 delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL autoinjectors on August 5, 2025, with completion targeted for August 26, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe asthma and chronic urticaria,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units valued at $1,594.16, with completion scheduled for August 18, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody therapeutic used primarily for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of XOLAIR 300 mg/2 ml auto-injector prefilled syringes. This competitive award, valued at $3,188.32 with firm fixed pricing, is scheduled for completion by August 18, 2025. The contract represents a direct delivery order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. As a pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $9,564.96 firm fixed-price delivery order for Xolair 300 mg/2 mL auto-injector units with a completion date of August 20, 2025. This non-set-aside award represents a competitive procurement action executed on July 30, 2025, with performance fulfillment at the vendor's Conshohocken, Pennsylvania location. Xolair (omalizumab) is a monoclonal antibody therapeutic commonly used in the treatment of moderate-to-severe allergic asthma...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,203.40 for XOLAIR 150 mg/ml syringes under a firm fixed price contract on August 8, 2025, with an ultimate completion date of August 29, 2025. This is a competitive award with no set-aside designation, and performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate-to-severe allergic asthma and chronic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes valued at $2,881.36, with an ultimate completion date of August 8, 2025. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL autoinjector units valued at $3,188.32. This firm fixed price delivery order, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $34,576.32 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes, with a completion date of August 22, 2025. This is a firm fixed price, non-set-aside contract awarded on August 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a...
- The Defense Logistics Agency awarded a $3,188.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for Xolair 300 mg/2 ml auto-injector units, with completion targeted for August 11, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered from AmerisourceBergen's...